Clostridium difficile disease and vancomycin-questionable clinical superiority

Clinical Infectious Diseases

Volumn 53, Issue 2, 2011, Pages 212-

  Tarchini, Giorgio ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; METRONIDAZOLE; VANCOMYCIN;

ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; CREATININE BLOOD LEVEL; DRUG TREATMENT FAILURE; HUMAN; LETTER; LEUKOCYTOSIS; PERIPHERAL NEUROPATHY; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; METRONIDAZOLE; TREATMENT OUTCOME; VANCOMYCIN;

EID: 79959767420     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir412     Document Type: Letter

References (5)

1. Studemeister A. Lack of health insurance coverage for oral vancomycin: it's time to tackle the elephant in the room. Clin Infect Dis 2011; 52:691-2.
2. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7. (Pubitemid 47101025)
3. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-55.
4. Zar FA, Davis MB. Reply to Bishara et al., Huggan et al., and Lawrence et al. Clin Infect Dis 2007; 45:1649-51.
5. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile- associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47:56-62. (Pubitemid 351920588)